Shift in corporate strategy for glaucoma drug development, new report finds

14 January 2019

The launch of 11 new therapies will drive growth in the glaucoma space, provide more options for patients, and stimulate further competition.

With no new classes of drugs having been developed for the treatment of glaucoma in the last 20 years, the focus of pharmaceutical companies has begun to shift towards the development of glaucoma drugs with novel mechanisms of action (MOAs), and this trend is expected to continue to 2026, says data and analytics company GlobalData.

In a previous report on the glaucoma market, GlobalData predicted that sales in the sector would reach $3.8 billion by 2026.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK